180 related articles for article (PubMed ID: 8062718)
1. [Pharmacological prevention and treatment of diabetic nephropathy].
Aitio ML
Duodecim; 1993; 109(6):503-11. PubMed ID: 8062718
[No Abstract] [Full Text] [Related]
2. Diabetic nephropathy: pathogenetic basis for treatment.
Reasner CA; DeFronzo R
Contemp Intern Med; 1994 Oct; 6(10):30-2, 35-40. PubMed ID: 10150289
[TBL] [Abstract][Full Text] [Related]
3. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
Barnas U; Mayer G
Wien Klin Wochenschr; 1995; 107(1):10-4. PubMed ID: 7871784
[TBL] [Abstract][Full Text] [Related]
4. The antiproteinuric effect of antihypertensive agents in diabetic nephropathy.
Gansevoort RT; Apperloo AJ; Heeg JE; de Jong PE; de Zeeuw D
Arch Intern Med; 1992 Oct; 152(10):2137-9. PubMed ID: 1417388
[No Abstract] [Full Text] [Related]
5. Approach to the treatment of diabetic nephropathy.
Burke JM
Pharm Pract Manag Q; 1997 Jul; 17(2):26-35. PubMed ID: 10168175
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
7. [RAS blockade in diabetic nephropathy. "Early intervention can dramatically decrease loss of function].
Ritz E
MMW Fortschr Med; 2004 Sep; 146(38):12. PubMed ID: 15532423
[No Abstract] [Full Text] [Related]
8. Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus.
Parving HH
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):30-1. PubMed ID: 11967794
[No Abstract] [Full Text] [Related]
9. [Diabetic nephropathy].
Metsärinne K
Duodecim; 2003; 119(24):2445-50. PubMed ID: 14870506
[No Abstract] [Full Text] [Related]
10. The renin-angiotensin system and diabetic nephropathy.
Gurley SB; Coffman TM
Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
[TBL] [Abstract][Full Text] [Related]
11. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
O'Donnell MJ; Rowe BR; Lawson N; Horton A; Gyde OH; Barnett AH
J Hum Hypertens; 1993 Aug; 7(4):333-9. PubMed ID: 8410924
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive review of antihypertensive agents providing renal protection.
Kalus JS; White CM
Conn Med; 2001 Oct; 65(10):587-91. PubMed ID: 11702517
[No Abstract] [Full Text] [Related]
14. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases].
Esnault V
Nephrol Ther; 2006 May; 2 Suppl 3():S193-6. PubMed ID: 17370850
[TBL] [Abstract][Full Text] [Related]
15. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy.
Lash JP; Bakris GL
Nephrol Dial Transplant; 1995 Oct; 10 Suppl 9():56-62. PubMed ID: 8643210
[No Abstract] [Full Text] [Related]
16. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
Wittmann I; Degrell P; Komáromy A; Molnár GA; Wagner Z; Wagner L; Mazák I; Nagy J
Orv Hetil; 2003 Mar; 144(13):613-9. PubMed ID: 12728786
[TBL] [Abstract][Full Text] [Related]
17. [Control of arterial pressure in diabetic nephropathy].
Luño J; García de Vinuesa S
Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
[No Abstract] [Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors improve nephrosis more quickly than calcium antagonists in diabetic patients.
Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
Nephron; 2000 Dec; 86(4):526-8. PubMed ID: 11124614
[No Abstract] [Full Text] [Related]
19. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
Fronczyk A; Majkowska L
Przegl Lek; 2007; 64(2):81-5. PubMed ID: 17892038
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blockers do not have an advantage over angiotensin-converting inhibitors [corrected].
Harman-Boehm I
Isr Med Assoc J; 2004 May; 6(5):296-8. PubMed ID: 15151373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
